Panitumumab
| Evidence Level: L5 | Predicted Indications: 51 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Panitumumab |
| DrugBank ID | DB01269 |
| Brand Names (EU) | Vectibix |
| Evidence Level | L5 |
| Predicted Indications | 51 |
| Top Prediction Score | 99.13% |
Approved Indication (EMA)
Vectibix is indicated for the treatment of adult patients with wild-type RAS metastatic colorectal cancer (mCRC): in first-line in combination with Folfox or Folfiri. in second-line in combination with Folfiri for patients who have received first-line fluoropyrimidine-based chemotherapy (excluding irinotecan). as monotherapy after failure of fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens.
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | drug-induced osteoporosis | 99.13% | DL |
| 2 | severe nonproliferative diabetic retinopathy | 99.05% | DL |
| 3 | diabetic retinopathy | 98.96% | DL |
| 4 | diabetic cataract | 98.90% | DL |
| 5 | nuclear senile cataract | 98.81% | DL |
| 6 | cortical cataract | 98.81% | DL |
| 7 | craniostenosis cataract | 98.77% | DL |
| 8 | mature cataract | 98.77% | DL |
| 9 | diabetes mellitus type 2 associated cataract | 98.77% | DL |
| 10 | immature cataract | 98.77% | DL |
| 11 | tetanic cataract | 98.77% | DL |
| 12 | senile cataract | 98.75% | DL |
| 13 | rectal cloacogenic carcinoma | 98.11% | DL |
| 14 | gallbladder adenosquamous carcinoma | 98.05% | DL |
| 15 | adenosquamous prostate carcinoma | 98.01% | DL |
| 16 | external ear basal cell carcinoma | 98.00% | DL |
| 17 | urethral verrucous carcinoma | 98.00% | DL |
| 18 | squamous cell carcinoma | 97.99% | DL |
| 19 | pancreatic adenosquamous carcinoma | 97.98% | DL |
| 20 | HER2 positive breast carcinoma | 97.98% | DL |
Showing top 20 of 51 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.